The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer
Inclusion Criteria:
Exclusion Criteria:
Huntsville, Alabama, United States
Pittsfield, Massachusetts, United States
Kalamazoo, Michigan, United States
Latham, New York, United States
Asheville, North Carolina, United States
Goldsboro, North Carolina, United States
Hendersonville, North Carolina, United States
Winston-Salem, North Carolina, United States
Columbus, Ohio, United States
Bend, Oregon, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Reading, Pennsylvania, United States
Charleston, South Carolina, United States
Ivins, Utah, United States
Ogden, Utah, United States
Provo, Utah, United States
St. George, Utah, United States
Bellevue, Washington, United States
Seattle, Washington, United States